Drug-mediated and cellular immunotherapy in multiple myeloma

Immunotherapy

Volumn 2, Issue 2, 2010, Pages 243-255

  Ritchie, David S ^a,b,c   Quach, Hang ^a,d   Fielding, Kate ^a   Neeson, Paul ^a  

^a Haematology and Immunology Translational Research Laboratory   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

Author keywords

Adoptive immunotherapy; Immunogenic cell death; Immunomodulatory drug; Myeloma; Vaccination

Indexed keywords

ANTHRACYCLINE; ANTIGEN; ANTINEOPLASTIC AGENT; BORTEZOMIB; CANCER VACCINE; CORTICOSTEROID; DENDRITIC CELL VACCINE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; INTERLEUKIN 6 ANTIBODY; LENALIDOMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LEY; PNEUMOCOCCUS VACCINE; POMALIDOMIDE; RITUXIMAB; TAXANE DERIVATIVE; THALIDOMIDE; UNCLASSIFIED DRUG; BORONIC ACID DERIVATIVE; IMMUNOLOGIC FACTOR; PYRAZINE DERIVATIVE; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL THERAPY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE PARALYSIS; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MEDIATOR; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; ACTIVE IMMUNIZATION; ANALOGS AND DERIVATIVES; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; DRUG EFFECTS; FORECASTING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PROCEDURES; TRANSPLANTATION; TUMOR ESCAPE;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CANCER VACCINES; COMBINED MODALITY THERAPY; FORECASTING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; MULTIPLE MYELOMA; PYRAZINES; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; THALIDOMIDE; TUMOR ESCAPE;

EID: 77953385584     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.9     Document Type: Review

References (144)

1. Jagannath S, Barlogie B: Autologous bone marrow transplantation for multiple myeloma. Hematol. Oncol. Clin. North Am. 6, 437-449 (1992).
2. Attal M, Harousseau JL, Stoppa AM et al.: Intensive therapy for high grade multiple myeloma (MM). N. Engl. J. Med. 335, 91-97 (1996).
3. Richardson PG, Sonneveld P, Schuster MW et al.: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487-2498 (2005).
4. Kumar SK, Rajkumar SV, Dispenzieri A et al.: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111 (5), 2516-2520 (2008).
5. Rajkumar SV: Treatment of myeloma: cure vs control. Mayo Clin. Proc. 83(10), 1142-1145 (2008).
6. Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5(4), 263-274 (2005).
7. Brown RD, Pope B, Murray A et al.: Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-b1 and interleukin-10. Blood 15, 98(10), 2992-2998 (2001).
8. Ratta M, Fagnoni F, Curti A et al.: Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100(1), 230-237 (2002).
9. Hegde S, Pahne J, Smola-Hess S: Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NF-kB binding activity and CCR7 expression. FASEB J. 18(12), 1439-1441 (2004).
10. Takahashi A, Kono K, Ichihara F, Sugai H, Fujii H, Matsumoto Y: Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinfammatory cytokines. Cancer Immunol. Immunother. 53(6), 543-550 (2004).
11. Cook G, Campbell JD, Carr CE, Boyd KS, Franklin IM: Transforming growth factor b from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J. Leukoc. Biol. 66(6), 981-988 (1999).
12. Brimnes MK, Svane IM, Johnsen HE: Impaired functionality and phenotypic profle of dendritic cells from patients with multiple myeloma. Clin. Exp. Immunol. 144(1), 76-84 (2006).
13. Jarahian M, Watzl C, Issa Y, Altevogt P, Momburg F: Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. Int. J. Cancer 120(12), 2625-2634 (2007).
14. Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2(4), 293-299 (2001).
15. Pratt G, Goodyear O, Moss P: Immunodefciency and immunotherapy in multiple myeloma. Br. J. Haematol. 138(5), 563-579 (2007).
16. Munshi NC: Immunoregulatory mechanisms in multiple myeloma. Hematol. Oncol. Clin. North Am. 11(1), 51-69 (1997).
17. Rawstron AC, Davies FE, Owen RG et al.: B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specifc to normal B-cell progenitors and plasma cell precursors. Br. J. Haematol. 100(1), 176-183 (1998).
18. Mills KH, Cawley JC: Abnormal monoclonal antibody-defned helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. Br. J. Haematol. 53(2), 271-275 (1983).
19. Ogawara H, Handa H, Yamazaki T et al.: High Th1/Th2 ratio in patients with multiple myeloma. Leuk. Res. 29(2), 135-140 (2005).
20. Frassanito MA, Cusmai A, Dammacco F: Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin. Exp. Immunol. 125(2), 190-197 (2001).
21. Quach H, Ritchie D, Neeson P et al.: Lymphoid subsets and regulatory T cell profles in patients with relapsed multiple myeloma in a subset of patients enrolled in the REVLITE trial (abstract). Presented at: Haematology Society of Australia and New Zealand Annual Scientifc Meeting. Perth, Australia, October (2008).
22. + T-cell responses are impaired in multiple myeloma. Br. J. Haematol. 121(6), 842-848 (2003).
23. Dhodapkar MV, Geller MD, Chang DH et al.: A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197(12), 1667-1676 (2003).
24. Subklewe M, Sebelin-Wulf K, Beier C et al.: Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum. Immunol. 68, 147-155 (2007).
25. Curiel TJ: Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117(5), 1167-1174 (2007).
26. Chen ML, Pittet MJ, Gorelik L et al.: Regulatory T cells suppress tumor-specifc CD8 T cell cytotoxicity through TGF-b signals in vivo. Proc. Natl Acad. Sci. USA 102(2), 419-424 (2005).
27. + helper T cell responses in cancer patients. Blood 106(3), 1008-1011 (2005).
28. + regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 66(20), 10145-10152 (2006).
29. + and NK lymphocytes in the direct cell-to-cell interaction. Clin. Immunol. 112(3), 258-267 (2004).
30. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9(2), 606-612 (2003).
31. Beyer M, Schultze JL: Regulatory T cells in cancer. Blood 108(3), 804-811 (2006).
32. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H: Increased populations of regulatory T cells in peripheral blood and tumor-infltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 9(12), 4404-4408 (2003).
33. Curiel TJ, Coukos G, Zou L et al.: Specifc recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004).
34. Joshua DE, Brown RD, Ho PJ, Gibson J: Regulatory T cells and multiple myeloma. Clin Lymphoma Myeloma 8(5), 283-286 (2008).
35. Prabhala RH, Neri P, Bae JE et al.: Dysfunctional T regulatory cells in multiple myeloma. Blood 107(1), 301-304 (2006).
36. Quach H, Ritchie D, Neeson P et al.: Regulatory T cells (Treg) are depressed in patients with relapsed/refractory multiple myeloma (MM) and increases towards normal range in responding patients treated with lenalidomide. Blood 112, 1696A (2008).
37. + regulatory T cells in patients with multiple myeloma. Blood 107(10), 3940-3949 (2006).
38. - abTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br. J. Haematol. 144(5), 686-695 (2009).
39. Dhodapkar KM, Barbuto S, Matthews P et al.: Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood, 112(7), 2878-2885 (2008).
40. + antigen-specifc autoimmune effectors in vitro and in vivo. J. Immunol. 181(5), 3137-3147 (2008)
41. Idler I, Giannopoulos K, Zenz T et al.: Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br. J. Haematol. DOI: 10.1111/j.1365-2141.2009.08014.x (2009) (Epub ahead of print).
42. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W: Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114(2), 357-359 (2009).
43. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206(7), 1457-1464 (2009).
44. Murugaiyan G, Saha B: Protumor vs antitumor functions of IL-17. J. Immunol. 183(7), 4169-4175 (2009).
45. Sato K, Suematsu A, Okamoto K et al.: Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203(12), 2673-2682. (2006).
46. Daynes RA, Araneo BA: Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin 2 and interleukin 4. Eur. J. Immunol. 19(12), 2319-2325 (1989).
47. Porrata LF, Inwards DJ, Ansell SM et al.: Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol. Blood Marrow Transplant. 14(7), 807-816 (2008).
48. Zinser E, Rössner S, Littmann L et al.: Inhibition of the proteasome infuences murine and human dendritic cell development in vitro and in vivo. Immunobiology 214(9-10), 843-851 (2009).
49. Arpinati M, Chirumbolo G, Nicolini B, Agostinelli C, Rondelli D: Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade). Bone Marrow Transplant. 43(3), 253-259 (2009).
50. Basler M, Lauer C, Beck U, Groettrup M: The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J. Immunol. 183(10), 6145-6150.(2009)
51. Quach H, Hsu A, Ritchie D et al.: In vivo antagonistic effects of dexamethasone on lenalidomide-induced NK cell activation. Blood 114 (2009) (Abstract 1639).
52. Rajkumar SV, Jacobus S, Callander NS et al.: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. DOI: doi:10.1016/S1470-2045(09)70284-0 (2009) (Epub ahead of print).
53. Augustson BM, Begum G, Dunn JA et al.: Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Reseach Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J. Clin. Oncol. 23, 9219-9226 (2005).
54. + T cells specifc for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood 106(13), 4217-4224 (2005).
55. Moshitsky S, Kukulansky T, Haimovich J et al.: Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin. Immunol. Cell Biol. 86(3), 261-267 (2008).
56. Cohen S, Haimovich J, Hollander N: B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice. J. Immunother. 28(5), 461-466 (2005).
57. Bergenbrant S, Yi Q, Osterberg A et al.: Modulation of anti-idiotypic immune response by immunization with autologous M-component protein in multiple myeloma patients. Br. J. Harmatol. 92(4), 840-846 (1996).
58. -specifc T-cell responses. Blood 91(7), 2459-2466 (1998).
59. Rasmussen T, Hansson L, Osterberg A et al.: Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 101(11), 4607-4610 (2003).
60. Hansson L, Abdalla AO, Moshfegh A et al.: Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin. Cancer Res. 13(5), 1503-1510 (2007).
61. Dhodapkar MV, Osman K, Teruya-Feldstein J et al.: Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun. 23(3), 9 (2003).
62. Qian J, Xie J, Hong S et al.: Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 110(5), 1587-1594 (2007).
63. Wang W, Nishioka Y, Oxaki S et al.: HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24-antibody. Cancer Immunol. Immunother. 58(6), 967-976 (2009).
64. Kawano T, Ahmad R, Nogi H et al.: MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells. Int. J. Oncol. 33(1), 153-159 (2008)
65. + T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undertermined signifcance (MGUS) and multiple myeloma. Blood 112(8), 3362-3372 (2008).
66. Curioni-Fontecedro A, Knights AJ, Tinguely M et al.: MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma. Leukemia 22(8), 1646-1648 (2008).
67. Tinguely M, Jenni B, Knights A et al.: MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer Sci. 99(4), 720-725 (2008).
68. Szmania S, Gnjatic S, Tricot G et al.: Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J. Immunother. 30(8), 847-854 (2007).
69. Dabadghao S, Bergenbrant S, Anton D et al.: Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br. J. Haematol. 100(4), 647-654 (1998).
70. Liso A, Stockerl-Goldstein KE, Aufferman-Gretzinger S et al.: Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant. 6(6), 621-627 (2000).
71. Reichardt VL, Milazzo C, Brugger W et al.: Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematalogica 88(10), 1139-1149 (2003).
72. Lacy MQ, Mandrekar S, Dispenzieri A et al.: Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am. J. Hematol. 84(12), 799-802 (2009).
73. Banerjee DK, Dhodapkar MV, Matayeva E et al.: Expansion of FOXP3high regulatory T cell by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108(8), 2655-2661 (2006).
74. Anderson KC: Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp. Hematol. 35(4 Suppl. 1), 155-162 (2007).
75. Hayashi T, Hideshima T, Akiyama M et al.: Ex vivo induction of multiple myeloma-specifc cytotoxic T lymphocytes. Blood 102(4), 1435-1442 (2003).
76. Lee JJ, Choi BH, Kang HK et al.: Induction of multiple myeloma-specifc cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purifed and optimized myeloma cell lysates. Leuk. Lymphoma 48(10), 2022-2031 (2007)
77. Rapoport A P, Stadmauer EA, Aqui N et al.: Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11 (11), 1230-1237. (2005).
78. Gahrton G, Tura S, Ljungman P et al.: Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J. Clin. Oncol. 13, 1312-1322 (1995).
79. Gahrton G, Tuna S, Ljungman P et al.: Allogeneic bone marrow transplantation in multiple myeloma. N. Engl. J. Med. 325, 1267-1273 (1991).
80. Crawley C, Iacobelli S, Björkstrand B et al.: Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 109, 3588-3594 (2007).
81. Bensinger WI, Buckner CD, Anasetti C et al.: Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 88, 2787-2793 (1996).
82. Tricot G, Vesole DH, Jagannath S et al.: Graft-versus-myeloma effect: proof of principle. Blood 87(3), 1196-1198 (1996).
83. Zeiser R, Bertz H, Spyridonidis A et al.: Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant. 34(11), 923-928 (2004).
84. Verdonck LF, Lokhorst HM, Dekker AW et al.: Graft-versus-myeloma effect in two cases. Lancet 347(9004), 800-801 (1996).
85. Lokhorst HM, Schattenberg A, Cornelissen JJ et al.: Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J. Clin. Oncol. 18(16), 3031-3037 (2000).
86. Björkstrand BB, Ljungman P, Svensson H et al.: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood Marrow Transplantation. Blood 88(12), 4711-4718 (1996).
87. Bruno B, Rotta M, Patriarca F et al.: Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 113(14), 3375-3382 (2009).
88. Bruno B, Rotta M, Patriarca F et al.: A comparison of allografting with autografting for newly diagnosed myeloma. N. Engl. J. Med. 356(11), 1110-1120 (2007).
89. + T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transplant. 43(5), 399-410 (2009).
90. Yi Q, Osterborg A, Bergenbrant S et al.: Idiotype-reactive T-cell subsets and tumour load in monoclonal gammopathies. Blood 86(8), 3043-3049 (1995).
91. van Rhee F, Szmania SM, Zhan F et al.: NY-ESO-I is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 105(10), 3939-3944 (2005).
92. Bernal M, Garrido P, Jiménez P et al.: Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells. Hum. Immunol. 70(10), 854-857 (2009).
93. Zheng C, Ostad M, Andersson M et al.: Natural cytotoxicity to autologous antigen-pulsed dendritic cells in multiple myeloma. Br. J. Haematol. 118(3) 778-785 (2002).
94. Frohn C, Hoppner M, Schlenke P et al.: Anti-myeloma activity of natural killer lymphocytes. Br. J. Haematol. 119(3), 660-666 (2002).
95. Alici E, Konstantinidis K V, Sutlu T et al.: Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. Exp. Hematol. 35(12), 1839-1846 (2007).
96. Alici E, Sutlu T, Bjorkstrand B et al.: Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 111(6), 3155-3162 (2008).
97. Gattinoni L, Powell DJ Jr, Rosenberg SA et al.: Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6(5), 383-393 (2006).
98. Noonan K, Matsui W, Serafni P et al.: Activated marrow-infltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res. 65(5), 2026-2034 (2005).
99. Rosenberg SA, Yannelli JR, Yang JC et al.: Treatment of patients with metastatic melanoma with autologous tumor-infltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86(15), 1159-1166 (1994).
100. Rosenberg SA, Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol.21(2), 233-240 (2009).
101. Westwood JA, Smyth MJ, Teng MW et al.: Adoptive transfer of T cells modifed with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc. Natl Acad. Sci. USA 102(52), 19051-19056 (2005).
102. Scott AM, Tebbutt N, Lee FT et al.: A Phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin. Cancer Res. 13(11), 3286-3292 (2007).
103. Hideshima T, Bergsagel PL, Kuehl WM et al.: Advances in biology of multiple myeloma: clinical applications. Blood 104(3), 607-618 (2004).
104. Quach H, Ritchie D, Stewart AK et al.: Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia DOI: 10.1038/leu.2009.236 (2009) (Epub ahead of print).
105. Corral LG, Haslett PA, Muller GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a. J. Immunol. 163(1), 380-386 (1999).
106. LeBlanc R, Hideshima T, Catley LP et al.: Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103(5), 1787-1790 (2004).
107. + subset. J. Exp. Med. 187(11), 1885-1892 (1998).
108. Schafer PH, Gandhi AK, Loveland MA et al.: Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J. Pharmacol. Exp. Ther. 305(3), 1222-1232 (2003).
109. Galustian C, Meyer B, Labarthe MC et al.: The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol. Immunother. 58(7), 1033-1045 (2009).
110. Dredge K, Marriott JB, Todryk SM et al.: Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J. Immunol. 168(10), 4914-4919 (2002).
111. Kronenberg M: Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23, 877-900 (2005).
112. Davies FE, Raje N, Hideshima T et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98(1), 210-216 (2001).
113. ®) CC-4047 enhances the proliferation and anti-tumour fuction of g d T cells. J. Immunother. 27, S50 (2004).
114. Hayashi T, Hideshima T, Akiyama M et al.: Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br. J. Haematol. 128(2), 192-203 (2005).
115. Chang DH, Liu N, Klimek V et al.: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108(2), 618-621 (2006).
116. + natural killer T cells using a-galactosyl ceramide-pulsed dendritic cells. J. Immunol. Methods 272(1-2), 147-159 (2003).
117. Carnaud C, Lee D, Donnars O et al.: Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163(9), 4647-4650 (1999).
118. + T cells and natural killer cells is essential for the antimetastatic effect of a-galactosylceramide. Blood 99(4), 1259-1266 (2002).
119. Eberl G, MacDonald HR: Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur. J. Immunol. 30(4), 985-992 (2000).
120. + T cells upon NK T or T cell activation. J. Immunol. 165(8), 4305-4311 (2000).
121. + tumor cells. Clin. Cancer Res. 14(14), 4650-4657 (2008).
122. Dallegri F, Patrone F, Frumento G, Sacchetti C: Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms. J. Natl Cancer Inst. 73(2), 331-339 (1984).
123. Tai YT, Li XF, Catley L et al.: Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 65(24), 11712-11720 (2005).
124. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS: Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodefcient mouse lymphoma model. Clin. Cancer Res. 11(16), 5984-5992 (2005).
125. Lapalombella R, Yu B, Triantafllou G et al.: Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 112(13), 5180-5189 (2008).
126. Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S, Carson WE 3rd: Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res. 66(1), 517-526 (2006).
127. Green DR, Ferguson T, Zitvogel L, Kroemer G: Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9(5), 353-363 (2009).
128. Panaretakis T, Joza N, Modjtahedi N et al.: The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ. 15(9), 1499-1509 (2008).
129. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G: Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol.8(1), 59-73 (2008).
130. Karin M, Yamamoto Y, Wang QM: The IKK NF-k B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3(1), 17-26 (2004).
131. Li Z W, Chen H, Campbell RA, Bonavida B, Berenson JR: NF-kB in the pathogenesis and treatment of multiple myeloma. Curr. Opin. Hematol. 15(4), 391-399 (2008).
132. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV: Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 109(11), 4839-4845 (2007).
133. Chatterjee M, Chakraborty T, Tassone P: Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy. Eur. J. Cancer 42(11), 1640-1652 (2006).
134. Klein B, Zhang XG, Jourdan M et al.: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-l. Blood 73, 517-526 (1989).
135. Vink A, Coulie P, Warnier G et al.: Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. J. Exp. Med. 172(3), 997-1000 (1990).
136. van Zaanen HC, Lokhorst HM, Aarden LA et al.: Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a Phase I dose-escalating study. Br. J. Haematol. 102(3), 783-790 (1998).
137. Podar K, Richardson PG, Chauhan D, Anderson KC: Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Expert Rev. Anticancer Ther. 7(4), 551-566 (2007).
138. Kastritis E, Charidimou A, Varkaris A, Dimopoulos MA: Targeted therapies in multiple myeloma. Target Oncol. 4(1), 23-36 (2009).
139. Prince HM, Hönemann D, Spencer A et al.: Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a Phase 2 study of pazopanib (GW786034). Blood 113(19), 4819-4820 (2009).
140. Tai Y T, Li XF, Catley L et al.: Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 65(24), 11712-11720 (2005).
141. Uno T, Takeda K, Kojima Y et al.: Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 12(6), 693-698 (2006).
142. Hilchey SP, Hyrien O, Mosmann TR et al.: Rituximab immunotherapy results in the induction of a lymphoma idiotype-specifc T-cell response in patients with follicular lymphoma: support for a 'vaccinal effect' of rituximab. Blood 113, 3809-3812 (2009).
143. Ayuk F, Zander A, Kröger N: Antitumor effects of polyclonal antithymocyte globulins: focus on B-cell malignancies and multiple myeloma. Ann. Hematol. 88(5), 401-404 (2009).
144. Coscia M, Mariani S, Battaglio S et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukaemia 18, 139-145 (2004).